Figure 5.

Combination treatment with CCX771 and enzalutamide (ENZ) inhibits C4–2B tumor growth and metastasis in vivo. A, C4–2B cells (1×10⁶ cells/site) were injected subcutaneously into ICR-SCID male mice. Mice were assigned into 4 groups (9 mice/group) and treated with vehicle, CCX771 (30 mg/kg), ENZ (25 mg/kg), or CCX771 + ENZ for 5 weeks. The tumor growth was monitored using caliper measurement. Values of tumor volume are mean ± SE. P-value was calculated using two-tailed Student’s t-test between groups. B, CXCR7 mRNA expression levels in tumor tissues were measured by RT-qPCR. P-value was calculated using two-tailed Student’s t-test between groups. C and D, C4–2B tumor metastases were assessed by quantification of human-specific Alu sequences in DNAs extracted from bone marrow from tibia and liver tissues.